Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02029430 · ClinicalTrials.gov registry record · Phase 2
A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma
A Phase 2 study, sponsored by ImmunityBio.
- Completed
- Registry status
- Phase 2
- Development phase
- 15
- Enrollment target
NCT02029430: Completed Phase 2 study, sponsored by ImmunityBio.
NCT02029430 is a Phase 2 study that has completed, run by ImmunityBio. The registered enrollment target is 15 participants, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT02029430, a Phase 2 study, has completed, sponsored by ImmunityBio.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 15 participants
- Enrollment target
Study Summary
This is a pilot study to determine the efficacy, kinetics and safety of aldoxorubicin in HIV positive subjects with Kaposi's sarcoma.
Primary Outcome
To evaluate the uptake of aldoxorubicin into the tumor and the objective response rate (complete and partial response) using RECIST 1.1 criteria in subjects with HIV-infected with Kaposi's sarcoma. Objective responses will be evaluated using the RECIST 1.1 criteria. Changes (i.e. improvements) in tumor measurements from baseline values will be assigned a status of CR or PR or SD. Objective response measurements will comprise the sum of CR plus PR. Complete Response (CR): disappearance of all t
Interventions
- DRUG 50 mg/m2 aldoxorubicin
- DRUG 100 mg/m2 aldoxorubicin
- DRUG 150 mg/m2 aldoxorubicin
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 15 participants |
| Start Date | 2014-04-03 |
| Est. Completion | 2016-04-25 |
| Phase | Phase 2 |
What the finished NCT02029430 record still lists
NCT02029430 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 15 participants, a relatively small participant target, below the 133-participant average among 30,622 other Phase 2 trials with a reported enrollment target (89% lower).
The record links to 0 conditions, and to 3 interventions - of which 50 mg/m2 aldoxorubicin is the first listed.
NCT02029430 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT02029430 about?
NCT02029430 is a clinical study titled "A Study to Investigate ALDOXORUBICIN in HIV-infected Subjects With Kaposi's Sarcoma". This is a pilot study to determine the efficacy, kinetics and safety of aldoxorubicin in HIV positive subjects with Kaposi's sarcoma.
What is the current status of trial NCT02029430?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 15 participants. The study started on 2014-04-03. Estimated completion is 2016-04-25.
What interventions are being tested in trial NCT02029430?
The interventions under investigation include: 50 mg/m2 aldoxorubicin (DRUG), 100 mg/m2 aldoxorubicin (DRUG), 150 mg/m2 aldoxorubicin (DRUG).
Who is sponsoring clinical trial NCT02029430?
This trial is sponsored by ImmunityBio, which has 46 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT02029430's enrollment target sits among peer trials
15 1919th of 2000 higher than 60 of 2,000 other Phase 2 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 2 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT01889381 · 15 participants · Phase 2
Human Craniomaxillofacial Allotransplantation
- NCT02530073 · 15 participants · NA
Trial of Fetoscopic Endoluminal Tracheal Occlusion (FETO) for CDH
- NCT02535936 · 15 participants · NA
Cortical Plasticity in Spastic Diplegia After Selective Dorsal Rhizotomy
- NCT02918474 · 15 participants · NA
Decision Making Tool in Supporting Decision Making in Contralateral Prophylactic Mastectomy in Patients With Newly Diagnosed Breast Cancer
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI